Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Inflammation Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1503648
This article is part of the Research Topic Inflammation and Lipid Signaling in Disease Pathogenesis View all 4 articles

Polyvinylalcohol-carbazate mitigates acute lung injury caused by hydrochloric acid

Provisionally accepted
Caijuan Dong Caijuan Dong 1,2Jielu Liu Jielu Liu 1Alessandro Quaranta Alessandro Quaranta 1Xu Jing Xu Jing 1Mu Nie Mu Nie 1Craig Wheelock Craig Wheelock 1Ben Murrell Ben Murrell 1Jonathan Coquet Jonathan Coquet 1Tim Bowden Tim Bowden 3Thomas Engstrand Thomas Engstrand 1Mikael Adner Mikael Adner 1*
  • 1 Karolinska Institutet (KI), Solna, Sweden
  • 2 Cardiovascular Research Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
  • 3 Department of Chemistry, Uppsala University, Uppsala, Uppsala, Sweden

The final, formatted version of the article will be published soon.

    Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are important causes of morbidity and mortality in critically ill patients. Gastric contents aspiration is one of the most common causes of ALI/ARDS. To date, there are still no specific and effective pharmacological treatments for ALI/ARDS. Polyvinylalcoholcarbazate (PVAC), a polymer that can bind endogenous aldehydes, neutralize oxidative stress and inhibit inflammatory factors, may be a potential treatment for ALI/ARDS. Methods: A hydrochloric acid (HCl) induced mouse model was employed to assess the effect of PVAC. The changes of lung mechanics, pulmonary edema, histology and immune cells, cytokines, and lipid mediators in bronchioalveolar lavage fluid (BALF) were investigated in HCl-challenged mice.In the HCl model, PVAC administration alleviated airway hyperresponsiveness and improved pulmonary edema and damage. In addition, it decreased the recruitment of neutrophils to the lung, and inhibited the increase of IL-6, TNF-α and leukotriene B4.Conclusions: These data indicates that PVAC is a potential candidate for the treatment of ALI/ARDS induced by aspiration of gastric acid or for the control of "asthma-like" symptoms in patients with gastroesophageal reflux.

    Keywords: Acute Respiratory Distress Syndrome, aspiration pneumonia, Oxidative Stress, pharmacological treatment, intranasal administration

    Received: 29 Sep 2024; Accepted: 06 Nov 2024.

    Copyright: © 2024 Dong, Liu, Quaranta, Jing, Nie, Wheelock, Murrell, Coquet, Bowden, Engstrand and Adner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Mikael Adner, Karolinska Institutet (KI), Solna, Sweden

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.